926293-55-2

Basic information

• Product Name: 6-Bromo-2-methylpyridine-3-carboxaldehyde
• Synonyms: 6-Bromo-2-methylpyridine-3-carboxaldehyde;6-BroMo-2-Methyl-pyridine-3-carbaldehyde;6-BroMo-2-Methylnicotinaldehyde;6-bromo-2-methyl-3-Pyridinecarboxaldehyde
• CAS NO: 926293-55-2
• Molecular Formula: C₇H₆BrNO
• Molecular Weight: 200
• Mol File: 926293-55-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 285℃
• Flash Point: 126℃
• Appearance: /
• Density: 1.577
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 6-Bromo-2-methylpyridine-3-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-2-methylpyridine-3-carboxaldehyde(926293-55-2)
• EPA Substance Registry System: 6-Bromo-2-methylpyridine-3-carboxaldehyde(926293-55-2)

Safety Data

• Hazardous Substances Data: 926293-55-2(Hazardous Substances Data)

Usage

General Description

6-Bromo-2-methylpyridine-3-carboxaldehyde, also known as 6-bromo-2-methyl-3-pyridinecarboxaldehyde, is an organic compound with the chemical formula C8H7BrNO. It is a yellow-brown solid and is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 6-Bromo-2-methylpyridine-3-carboxaldehyde is a versatile building block in organic synthesis, particularly in the production of various pyridine derivatives. It is also utilized as a reagent in organic reactions, such as in the synthesis of heterocyclic compounds and in the preparation of complex molecules for medicinal chemistry research. Additionally, 6-Bromo-2-methylpyridine-3-carboxaldehyde is used in the development of dyes and pigments, and has applications in the field of materials science.

Upstream product

• 39919-65-8 2,5-dibromo-6-methylpyridine 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 926643-30-3 C₁₄H₁₁NO₃S 
• 926305-05-7 6-(4-methoxy-phenoxy)-2-methyl-pyridine-3-carbaldehyde 
• 926305-06-8 6-(4-methoxy-phenylsulfanyl)-2-methyl-pyridine-3-carbaldehyde 
• 926641-03-4 6-(4-bromo-3-methyl-phenoxy)-2-methyl-pyridine-3-carbaldehyde 
• 926294-67-9 4-[(5-formyl-6-methylpyridin-2-yl)oxy]benzonitrile 
• 926294-64-6 methyl 4-((5-formyl-6-methylpyridin-2-yl)oxy)benzoate 
• 926302-33-2 6-(4-bromo-2-fluoro-phenoxy)-2-methyl-pyridine-3-carbaldehyde 
• 926295-88-7 [4-(5-formyl-6-methyl-pyridin-2-yloxy)-phenyl]-acetic acid methyl ester 
• 926305-00-2 [4-(5-formyl-6-methyl-pyridin-2-yloxy)-phenoxy]-acetic acid tert-butyl ester 
• 1446819-40-4 tert-butyl 4-[[2-methyl-6-(2-methylphenyl)pyridin-3-yl]methyl]piperazine-1-carboxylate 
• 1446819-41-5 1-[[2-methyl-6-(2-methylphenyl)pyridin-3-yl]methyl]piperazine 
• 1446818-14-9 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[2-methyl-6-(2-methylphenyl)pyridin-3-yl]methyl]piperazine-1-carboxylate 
• 926295-40-1 methyl 4-[(5-formyl-6-methylpyridin-2-yl)sulfanyl]benzoate 

Relevant articles and documents

MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS

The invention relates to modulators of Embryonic Ectoderm Development (EED) and/or Polycomb Repressive Complex 2 (PRC2) useful in the treatment of disorders and diseases associated with EEC and PRC2, being macrocyclic azolopyridine derivatives and compositions thereof of Formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer, isomer, or tautomer thereof, wherein X1, X2, X3, A1, A2, Y, R1, R2, R3, and R4 are as described herein.

PYRIDYLPYRIDONE DERIVATIVE USEFUL AS A RET KINASE INHIBITOR IN THE TREATMENT OF IBS AND CANCER

This invention relates to a novel compound which is an inhibitor of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing it, to processes for its preparation, and to its use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity. Formula (I)